Skip to main content
Renal Risk Minimisation Material: Tenofovir Disoproxil for adolescent children with chronic hepatitis B
For Healthcare Professionals
This brochure provides important advice on the management of potential renal and bone effects of tenofovir disoproxil in adolescent patients with chronic hepatitis B aged 12 to <18 years, and on the dosing recommendations for tenofovir disoproxil in this population.
